Age-Related Macular Degeneration

A multivariate linear mixed model regression analysis of eyes without DR indicates no statistically significant differences in retinal venular or arteriolar width between subtypes and patients with classical T2D.

A post-hoc analysis of the XIRIUS and XOLARIS trials suggest the gene therapy improved some visual function for patients with XLRP, but the reported SAEs require further safety assessments.

Based on the findings, investigators suggest the evaluation of diastolic blood pressure be considered as a therapeutic measure in patients with glaucoma.

An analysis of Denmark's FORSYN study suggests new advances in the treatment of chorioretinal vascular diseases have significantly reduced vision loss.

Data indicate 2 out of 5 patients utilized LVR services among those who received a referral recommendation during the CDSS active phase, while onsite LVR service provision increased utilization rates.

An analysis of the Lifelines cohort revealed DED had a significant impact on work functioning, comparable to the impact of other chronic diseases considered function impairing.

Phase 2b findings suggest VEGF-C/D inhibition with 2.0 mg OPT-302 in combination with ranibizumab achieves superior vision gains compared to the current standard of care for nAMD.

The January 2023 ophthalmology month in review features modifications in age-related macular degeneration risk, links between ophthalmic disease and quality of life, and complications during cataract surgery.

Real-world data suggest nAMD eyes can extend injection intervals by switching to brolucizumab from other anti-VEGF therapies, while maintaining vision and reducing CMT.

Repeated injections with preoperative povidone-iodine application was associated with reduced meibomian gland loss, increased tear volume, and reduced signs of inflammation.

Drs Eleonora M. Lad, David R. Lally, Jaynath R. Sridhar, and Nancy M. Holekamp share takeaways for health care professionals taking care of patients with geographic atrophy and earlier stages of age-related macular degeneration.

Eleonora M. Lad, MD, PhD, shares how advances in ocular imaging, including AI tools, can improve diagnosis of geographic atrophy going forward.

The phase 3 GOBI study endpoints was significantly greater with NOV03 versus hypotonic saline on the change from baseline at Week 8.

The retrospective study reported the presence of ADAs was associated with lower drug levels, and higher ADA levels were associated with increased risk of TNFi therapy failure.

The lowest mean utility value was observed in the most severe disease state of constant diplopia and large proptosis.

The data from the DPPOS cohort report no difference in AMD presence or severity between metformin, intensive lifestyle intervention, and placebo arms.

Complete healing occurred after 4 weeks in 6 of the 10 RGN-259-treated subjects and in 1 of the 8 placebo-treated subjects.

Drs Eleonora M. Lad, David R. Lally, Jaynath R. Sridhar, and Nancy M. Holekamp discuss the need to improve the referral process through educating physicians about geographic atrophy.

A panel of experts discuss what clinics need to consider when introducing new geographic atrophy treatments in their practice.

Study data show the five-year incidence of fibrosis, atrophy, and MH were 34%, 26%, and 8%, respectively.

Cross-sectional data showed that rEZR reduced with increasing age, while longitudinal data indicate rEZR declined at a rate of ‒2.1 AU per year.

A look at the defining moments of the past year and what is expected to come in 2023.

Drs Eleonora M. Lad, David R. Lally, Jayanth Sridhar, and Nancy M. Holekamp share insights to ensure adherence to therapy once started.

An expert panel discusses the role of complement C3 vs C5 therapies and provides guidance for treatment selection in geographic atrophy.

The ERF and ERF-free groups had similar best visual acuity gains from baseline to week 52.

Drs Eleonora M. Lad and Nancy M. Holekamp review other emerging treatment options for geographic atrophy.

A panel of experts comments on the safety data of pegcetacoplan in geographic atrophy and their approach to monitoring patients.

A retrospective cohort analysis of patients in Finland show a notable overlap of the 2 forms of vision loss.

Eleonora M. Lad, MD, PhD, shares her approach to treating subfoveal lesions and geographic atrophy in both eyes.

Drs Eleonora M. Lad, David R. Lally, Jaynath R. Sridhar, and Nancy M. Holekamp discuss pegcetacoplan dose frequency in treating geographic atrophy.